Huang Chen

500 Dongchuan Road
Shanghai, 200241, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Targeting WFS1 overcomes KRASG12D dependency and adaptive resistance to KRAS inhibition in pancreatic cancer.

Targeting WFS1 overcomes KRASG12D dependency and adaptive resistance to KRAS inhibition in pancreatic cancer.

Journal: NPJ precision oncology

Published: October 13, 2025

IRE1α inhibitor reduces cisplatin resistance in ovarian cancer by modulating IRE1α/XBP1 pathway.

IRE1α inhibitor reduces cisplatin resistance in ovarian cancer by modulating IRE1α/XBP1 pathway.

Journal: Cellular oncology (Dordrecht, Netherlands)

Published: October 24, 2024

Correction: Targeting STAT3 by a small molecule suppresses pancreatic cancer progression.

Correction: Targeting STAT3 by a small molecule suppresses pancreatic cancer progression.

Journal: Oncogene

Published: June 05, 2024

The small-molecule drug homoharringtonine targets HSF1 to suppress pancreatic cancer progression.

The small-molecule drug homoharringtonine targets HSF1 to suppress pancreatic cancer progression.

Journal: American journal of cancer research

Published: January 10, 2024

Discovery of the Highly Selective and Potent STAT3 Inhibitor for Pancreatic Cancer Treatment.

Discovery of the Highly Selective and Potent STAT3 Inhibitor for Pancreatic Cancer Treatment.

Journal: ACS central science

Published: November 23, 2023

WB518, a novel STAT3 inhibitor, effectively alleviates IMQ and TPA-induced animal psoriasis by inhibiting STAT3 phosphorylation and Keratin 17.

WB518, a novel STAT3 inhibitor, effectively alleviates IMQ and TPA-induced animal psoriasis by inhibiting STAT3 phosphorylation and Keratin 17.

Journal: International immunopharmacology

Published: September 17, 2023

Selectively targeting BCL6 using a small molecule inhibitor is a potential therapeutic strategy for ovarian cancer.

Selectively targeting BCL6 using a small molecule inhibitor is a potential therapeutic strategy for ovarian cancer.

Journal: International journal of biological sciences

Published: May 18, 2023

Discovery of a Highly Potent and Orally Bioavailable STAT3 Dual Phosphorylation Inhibitor for Pancreatic Cancer Treatment.

Discovery of a Highly Potent and Orally Bioavailable STAT3 Dual Phosphorylation Inhibitor for Pancreatic Cancer Treatment.

Journal: Journal of medicinal chemistry

Published: October 25, 2022

Selective PPARγ modulator diosmin improves insulin sensitivity and promotes browning of white fat.

Selective PPARγ modulator diosmin improves insulin sensitivity and promotes browning of white fat.

Journal: The Journal of biological chemistry

Published: August 04, 2022

Discovery of 2-Amino-3-cyanothiophene Derivatives as Potent STAT3 Inhibitors for the Treatment of Osteosarcoma Growth and Metastasis.

Discovery of 2-Amino-3-cyanothiophene Derivatives as Potent STAT3 Inhibitors for the Treatment of Osteosarcoma Growth and Metastasis.

Journal: Journal of medicinal chemistry

Published: April 27, 2022

Selectively Targeting STAT3 Using a Small Molecule Inhibitor is a Potential Therapeutic Strategy for Pancreatic Cancer.

Selectively Targeting STAT3 Using a Small Molecule Inhibitor is a Potential Therapeutic Strategy for Pancreatic Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 28, 2022

The natural product trienomycin A is a STAT3 pathway inhibitor that exhibits potent in vitro and in vivo efficacy against pancreatic cancer.

The natural product trienomycin A is a STAT3 pathway inhibitor that exhibits potent in vitro and in vivo efficacy against pancreatic cancer.

Journal: British journal of pharmacology

Published: October 19, 2020

Showing 1-12 of 15

Last Updated: 09/26/2026